Company news

Guardant Health, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Guardant Health Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Outlook

February 21, 2024

Guardant Health to Report Fourth Quarter and Full Year 2023 Financial Results on February 22, 2024

January 31, 2024

Guardant Health to present data at ASCO GI supporting use of liquid biopsy to predict colon cancer recurrence

January 16, 2024

Guardant Health Announces Preliminary Fourth Quarter and Full Year 2023 Results

January 7, 2024

Guardant Health and Hikma Partner to Offer Cancer Screening and Comprehensive Genomic Profiling Tests in the Middle East and North Africa

January 7, 2024

Guardant Health Appoints Terilyn Juarez Monroe as Chief People Officer

January 1, 2024

Guardant Health Announces $90.7 Million Registered Direct Offering with Baillie Gifford

December 20, 2023

Guardant Health to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

December 19, 2023

Guardant Health Announces Tentative Date of FDA Advisory Panel Review of Shield™ Blood Test

December 18, 2023

Cancer Research UK and Guardant Health Launch Collaboration to Advance Cancer Research and Clinical Development Activities

December 3, 2023

Guardant Health to present data at San Antonio Breast Cancer Symposium demonstrating utility of liquid biopsy in biomarker identification, therapy selection and residual disease detection

November 29, 2023

Guardant Health to Appeal Federal District Court Verdict

November 14, 2023

Guardant Health launches Shield blood-based screening test for colorectal cancer in South Korea

November 11, 2023

Guardant Health Reports Third Quarter 2023 Financial Results and Increases Revenue Guidance

November 5, 2023

Guardant Health to Participate in Upcoming November Investor Conferences

November 2, 2023

Guardant Health, Flatiron Health Announce Integration of Guardant Genomic Profiling Tests Into OncoEMR® Platform

October 30, 2023

Guardant Health to Report Third Quarter 2023 Financial Results on November 6, 2023

October 15, 2023

Guardant Health Receives Coverage for Guardant Reveal™ from Geisinger Health Plan

September 5, 2023

Guardant Health Receives Regulatory Approval in Japan for Guardant360® CDx as Companion Diagnostic to ENHERTU® for Treatment of Non-Small Cell Lung Cancer Patients with HER2 Mutations

September 4, 2023

Guardant Health Provides Update on COBRA Study, Restates Confidence in MRD Test

August 31, 2023

Guardant Health to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference

August 30, 2023

Guardant Health to Host Investor Day on September 7, 2023

August 16, 2023

Guardant Health Reports Second Quarter 2023 Financial Results and Increases Revenue Guidance

August 2, 2023

Guardant resolves pending litigation with Illumina and enters into new agreement to advance long-term commercial partnership and cancer research

July 31, 2023

Guardant Health receives first commercial payor coverage for Guardant Reveal™ test from Blue Cross and Blue Shield of Louisiana

July 19, 2023

Guardant Health to Report Second Quarter 2023 Financial Results on August 3, 2023

July 11, 2023

Guardant Health announces reimbursement approval of Guardant360® CDx liquid biopsy test in Japan

July 4, 2023

Guardant Health to present 17 scientific abstracts highlighting contribution of its blood tests and real-world data to advances in precision oncology and cancer screening at 2023 ASCO annual meeting

May 30, 2023

Guardant Health Receives Regulatory Approval from Singapore's Health Sciences Authority for Guardant360® CDx blood test for patients with advanced solid cancers

May 28, 2023

Guardant Health to Participate in Upcoming June Investor Conferences

May 25, 2023

Guardant Health Secures Coverage From Major US Commercial Health Insurers for Guardant360® Blood Test for Comprehensive Genomic Profiling

May 16, 2023

Guardant Health Releases Inaugural ESG Report

May 15, 2023

Guardant Health Reports First Quarter 2023 Financial Results

May 8, 2023

Guardant Health presents additional information from ECLIPSE study at 2023 Digestive Disease Week on the performance of Shield™ blood test

May 8, 2023

Guardant Health Announces Additions to Leadership Team

May 7, 2023

Guardant Health Announces ECLIPSE Study Update Call on May 9, 2023

May 4, 2023

Guardant Health to Participate in the BofA Securities 2023 Healthcare Conference

April 26, 2023

Guardant Health and Parker Institute for Cancer Immunotherapy (PICI) launch research collaboration to study connection between cancer biomarkers and immunotherapy treatment response

April 24, 2023

Guardant Health announces new data to be presented at 2023 Digestive Disease Week showcasing the potential of its blood-based technology to detect colorectal cancer

April 20, 2023

Guardant Health to Report First Quarter 2023 Financial Results on May 9, 2023

April 18, 2023

Guardant Health Receives Medicare Coverage for Guardant360 Response™ to Monitor Cancer Patient Response to Immunotherapy

April 17, 2023

Guardant Health to Present Data From 14 Studies Highlighting Advances in Precision Oncology and Cancer Screening at 2023 AACR Annual Meeting

April 10, 2023

Guardant Health collaborates with The Ohio State University Comprehensive Cancer Center to study colorectal cancer screening adherence

March 20, 2023

Guardant Health submits premarket approval application to the U.S. Food and Drug Administration for Shield™ blood test

March 9, 2023

Musa Tariq Joins Guardant Health Board of Directors

February 26, 2023

Guardant Health Reports Fourth Quarter and Full Year 2022 Financial Results and Provides 2023 Outlook

February 22, 2023

Guardant Health to Participate in Upcoming March Investor Conferences

February 16, 2023

Guardant Health Initiates New Study to Examine the Impact of Shield™ Blood Test to Increase Screening Compliance for Colorectal Cancer

February 14, 2023

Guardant Health receives coverage from UnitedHealthcare for Guardant360® CDx blood test as companion diagnostic in advanced lung and breast cancer

February 7, 2023

Magistrate Judge Issues Favorable Recommendation Regarding Guardant Health’s Motion to Dismiss Lawsuit Brought by Illumina

February 1, 2023

← Newer news releases · Older news releases →

Calls

The 5 newest of 21 calls. Every call is listed under its year.

Decks

The 5 newest of 49 decks. Every deck is listed under its year.